Detecting minimal residual disease may be key to preventing ovarian cancer recurrence
August 27, 2025
Key takeaways:
- Women who had minimal residual disease following first-line ovarian cancer treatment had significantly worse OS.
- Many women who appeared in remission had surgically- or ctDNA-detected minimal residual disease.
UPDATES AND NEWS
Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative | The ASCO Post
At a Turning Point for RAS-directed Therapies, Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative
How scientists found a weakness in one of the deadliest ‘undruggable’ cancers | The Washington Post
Radical Collaboration: A Cancer Funder Seeks to Solve the Problem of Siloed Research | Inside Philanthropy
BE PART OF THE MISSION
Stay Informed, Make an Impact
Subscribe
Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.
Give
Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 2.
